Effect of caspase-9 inhibitor on lymphoid and myeloid progenitors derived from cord blood hematopoietic stem cells
. | . | Treatment . | . | . | ||
|---|---|---|---|---|---|---|
| Cell type . | Time 0 . | DMSO . | C9i . | PCi . | ||
| CD19+ | 1.5 | 46.5 ± 1.4 | 56.0 ± 3.2* | 39.5 ± 1.8* | ||
| CD33+ | < 10 | 27.9 ± 3.9 | 22.3 ± 1.2 | 18.0 ± 3.9* | ||
. | . | Treatment . | . | . | ||
|---|---|---|---|---|---|---|
| Cell type . | Time 0 . | DMSO . | C9i . | PCi . | ||
| CD19+ | 1.5 | 46.5 ± 1.4 | 56.0 ± 3.2* | 39.5 ± 1.8* | ||
| CD33+ | < 10 | 27.9 ± 3.9 | 22.3 ± 1.2 | 18.0 ± 3.9* | ||
CD19+/PI- and CD33+/PI- (ie, CD19-/PI-) cells were sorted and tested for sensitivity to C9i as described in “Materials and methods.” Cells were cultured in triplicate with DMSO, C9i, or PCi; harvested after 18 hours; and stained with annexin V. Values are mean ± SD of the percentage of total annexin V+ cells (PI+ and PI-). Time 0 represents the percentage of annexin V+ events immediately after cell sorting.
P < .05 compared with DMSO control by Student t test